Targeted therapies in epilepsies.

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Drug-resistant epilepsy remains a significant challenge despite advances in antiseizure medications.
• Precision medicine offers targeted treatment strategies for rare pediatric epilepsies.
• Historical examples like pyridoxine for antiquitin deficiency and ketogenic diet for GLUT1 deficiency syndrome illustrate precision approaches.

Purpose of the Study:

• To explore the potential of precision medicine in treating rare pediatric epilepsies.
• To assess the translation of preclinical findings into clinical efficacy for drug-resistant epilepsy.
• To discuss the challenges and future directions in precision epilepsy treatment.

Main Methods:

• Review of existing literature on precision medicine in epilepsy.
• Analysis of preclinical evidence and clinical trial outcomes.
• Case examples of successful and challenging precision treatments.

Main Results:

• Preclinical research has identified numerous compounds for epilepsy treatment.
• Clinical trials, such as everolimus for tuberous sclerosis complex, show promise.
• Translational challenges exist, as seen with quinidine in KCNT1-related epilepsy, with heterogeneous outcomes.

Conclusions:

• Precision medicine holds potential for mechanism-driven treatments in rare epilepsies.
• Clinical trial validation is crucial for compounds identified at the preclinical level.
• The overall efficacy and disease-modifying effects of these precision approaches in drug-resistant epilepsy require further investigation.